To investigate the differences in the therapeutic approach to juvenile dermatomyositis (JDM) between pediatric rheumatology centers in Europe (EU) and Latin America (LA).
Objective
To investigate the differences in the therapeutic approach to juvenile dermatomyositis (JDM) between pediatric rheumatology centers in Europe (EU) and Latin America (LA).
Methods
490 patients with JDM and disease duration > 2 years seen in 27 centers in EU (Italy, UK) and LA (Argentina, Brazil, Mexico) after 1980 were enrolled in a multinational, multicenter study aimed to investigate the long-term disease outcome. Median follow-up duration was 7.7 years (range 2-25.2 years). Gender ratio, onset age, and follow-up duration were comparable between EU and LA patients. At study visit, EU patients had a greater frequency of active disease, as measured with MDAA (51.1% vs. 35.2%) and DAS (64.8% vs. 54%), whereas LA patients had a greater frequency of muscle weakness, as measured with the CMAS (62.9% vs. 44.3%), and muscle damage, as measured with the MDI (41% vs. 30.1%). Table 1 shows the frequency of drugs administered to JDM patients in EU and LA centers.
Results

Conclusion
Use of pulse iv steroids, CyA, AZA and CPM was more common in EU centers, whereas LA centers used more frequently MTX and AM. EU and LA centers administered iv Ig with equal frequency. 
